Navigation Links
Pre-Clinical Data Show Intracellular Pathways Affected by ONCONASE(R)
Date:2/21/2008

SOMERSET, N.J., Feb. 21 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that in vitro and in vivo data presented at the 5th Cancer Drug Research & Development conference show the genes affected and biological pathways impacted by ONCONASE stimulated intracellular events as revealed by expression profiling of human malignant mesothelioma cell lines. Data presented also show that ONCONASE conjugates effectively kill human cancer cells in cell culture and murine models of cancer.

Susanna Rybak, Ph.D., a member of Alfacell's scientific advisory board, presented a poster entitled "ONCONASE (ranpirnase): Intracellular Activity and Extracellular Selectivity." The data demonstrated that 181 genes were consistently up- and down-regulated by ONCONASE and that the genes involved in triggering apoptosis (programmed cell death) and the intracellular MAPK signaling pathway were impacted by ONCONASE in vitro. Additionally, pre-clinical data in mice demonstrated the relative potency of chemical conjugates of ONCONASE. These findings further support the research of next generation targeted ONCONASE fusion proteins in an effort to develop compounds with improved tumor penetrating abilities. The research was conducted in collaboration with Alfacell at Fox Chase Cancer Center and the University of Duisburg-Essen.

"This work may explain the intrinsic anti-tumor activity seen after ONCONASE treatment through the identification of the specific genes affected and the biological pathways impacted," said Dr. Rybak. "Additionally, this data is helping us to better understand the optimal intracellular pathways for developing antibody targeted ONCONASE compounds."

"The data presented further illuminates the potential for ONCONASE to simultaneously switch on and off numerous genes controlling major regulatory processes in the cell life cycle, and underscores that ONCONASE works selectively and does not appear to kill cells indiscriminately," added Kuslima Shogen, Alfacell's chief executive officer. "This research represents an important step forward in our continuing efforts to create targeted ONCONASE fusion proteins and to bring them forward into the clinic."

About ONCONASE(R)

ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of

ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media and Investor Contact:

David Schull or Wendy Lau

Russo Partners

212-845-4271

david.schull@russopartnersllc.com

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
4. Clinical Trial Participation Unaffected by Disclosure of Investigators Financial Stake, Food and Drug Law Journal Article Finds
5. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
6. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
7. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the "Dental ... ... markets for Dental Implants in US$ Million. The report provides separate comprehensive ... , Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 through ...
(Date:3/24/2017)... 24, 2017 FinancialBuzz.com News Commentary  ... According to ... cannabis market research, the legal cannabis market is projected to ... despite conflicting signals from the current presidential administration. The report ... two biggest drivers of growth in this industry are the ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... and Diagnostics, 2017 - 2035" report to their offering. ... The Deep Learning: Drug ... future outlook of the growing market of deep learning solutions within ... learning algorithms have emerged as a novel solution to generate relevant ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 24, 2017 , ... Mlynarek Insurance Agencies, a Detroit area ... owners across eastern Michigan, is connecting with the Oxford/Orion FISH Food Pantry for ... The Oxford/Orion FISH Food Pantry works to ensure homeless, hungry, and underprivileged families ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June 9, 2017, Cassie ... Litigation seminar in Chicago, Illinois. She will present on: , Filing Benefit ... under ERISA involve claims for long-term disability benefits. This session will address ...
(Date:3/24/2017)... Frederick, Maryland (PRWEB) , ... March 24, 2017 ... ... LLC, is the first Certified Medical Reiki™ Master in Frederick, MD. Judy says, ... and their caregivers during what is often a very difficult and challenging time.” ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
(Date:3/23/2017)... TX (PRWEB) , ... March 23, 2017 , ... ... clinic, located at 960 Gruene Road in Building 2. The clinic is the group’s ... Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things full ...
Breaking Medicine News(10 mins):